AI assistant
Bure Equity — Major Shareholding Notification 2017
Apr 19, 2017
2899_iss_2017-04-19_2e4e6831-eda2-40c6-ada9-219e9b5d4d4c.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
PRESS RELEASE
Stockholm, 19 April 2017
The information contained herein is subject to the disclosure requirements of Bure Equity AB (publ) under the Swedish Securities Market Act. The information was publicity communicated on 19 April 2017 at 9.00 a.m. CET.
Bure's holding in Xvivo Perfusion AB
Xvivo Perfusion AB (publ) decided on the Extraordinary General Meeting on April 10, 2017, to conduct a directed share issue to institutional investors. This issue was registered at the Swedish Companies Registration Office on April 13, 2017. Consequently, Bure Equity AB's holding in Xvivo Perfusion AB decreased from 20.7% to 18.8%.
Bure Equity AB's share of capital and votes amounts to 18.8%.
Bure Equity AB (publ)
Contact at Bure: Henrik Blomquist, CEO Tel. +46 (0)8 614 00 20